9,066 Shares in Sanofi (NASDAQ:SNY) Purchased by Good Steward Wealth Advisors LLC

Good Steward Wealth Advisors LLC purchased a new position in Sanofi (NASDAQ:SNY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,066 shares of the company’s stock, valued at approximately $503,000.

A number of other large investors also recently bought and sold shares of SNY. Bessemer Group Inc. raised its holdings in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. acquired a new stake in Sanofi during the 4th quarter worth approximately $31,000. UMB Bank n.a. raised its holdings in Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock valued at $62,000 after buying an additional 264 shares during the period. Whipplewood Advisors LLC acquired a new position in Sanofi during the fourth quarter valued at approximately $76,000. Finally, AdvisorNet Financial Inc grew its stake in Sanofi by 16.4% during the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after buying an additional 227 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $47.62 on Friday. The firm has a 50-day moving average of $51.31 and a two-hundred day moving average of $52.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The stock has a market cap of $116.79 billion, a P/E ratio of 17.01, a PEG ratio of 0.98 and a beta of 0.50. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the business posted $1.78 earnings per share. Sanofi’s revenue for the quarter was down 11.0% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a $2.0369 dividend. This represents a dividend yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi’s dividend payout ratio is presently 57.14%.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research reports. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective on the stock. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and an average price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.